OneStopList

Gods and goddesses

Apollo Hospitals Results: Q3 FY25 Net Profit Up 24%

Updated November 17, 2026

Apollo Hospitals Enterprise Ltd reported a consolidated net profit of ₹385 crore for the third quarter of fiscal year 2024-25 (Q3 FY25), a 24% increase from ₹310 crore in the same quarter last year. Revenue from operations rose 14% year-on-year to ₹5,587 crore, driven by growth in its core hospital business and a rebound in international patient volumes.

Quarterly Financial Highlights

The company’s Q3 FY25 results, announced in February 2025, showed strong performance across all segments. The hospital segment, which contributes the bulk of revenue, saw occupancy improve to 71% from 68% a year earlier. Average revenue per occupied bed (ARPOB) increased to approximately ₹68,000 per day, up from ₹62,000 in Q3 FY24.

  • Consolidated EBITDA grew 18% to ₹1,020 crore, with margins expanding to 18.2% from 17.5%.
  • Pharmacy distribution (Apollo 24/7 and retail) posted revenue of ₹1,850 crore, up 12%, though margins remained thin at around 3%.
  • Diagnostics (Apollo Health & Lifestyle) grew 11% to ₹410 crore, with same-store sales growth of 8%.
  • International patient revenue grew 22%, led by patients from Bangladesh, the Middle East, and Africa.

How Apollo Reports Its Financials

Apollo Hospitals follows Indian Accounting Standards (Ind-AS) for its consolidated financial statements. The company reports under four main segments: Hospitals, Pharmacy, Diagnostics, and Others (which includes insurance and retail health). Results are released quarterly, typically in February, May, August, and November, followed by an earnings call with analysts.

Investors should note that Apollo’s fiscal year runs April to March, so Q3 refers to October-December. The company’s stock is listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), and its ADRs trade on the NYSE under the ticker APH.

Key Drivers Behind the Growth

Several factors contributed to the improved results. The hospital segment benefited from higher surgical volumes, especially in oncology, cardiology, and orthopedics. The company added 1,200 beds during the year, bringing total capacity to over 12,000 beds across 80+ hospitals. Apollo also expanded its day-care surgery centers, which operate at higher margins than traditional inpatient care.

Cost control played a role too. Employee costs as a percentage of revenue declined to 22% from 23.5%, while consumables and drug costs were kept flat despite inflation. The company’s digital platform, Apollo 24/7, crossed 10 million monthly active users, driving pharmacy sales and preventive health checkups.

Comparing to Previous Quarters and Peers

Apollo’s Q3 FY25 results marked the fifth consecutive quarter of double-digit profit growth. In Q2 FY25, net profit was ₹360 crore, so the sequential improvement was 7%. Compared to peers, Apollo’s margin expansion outpaced Fortis Healthcare (EBITDA margin ~16%) but lagged Max Healthcare (EBITDA margin ~28%), which benefits from a higher proportion of tertiary-care beds in North India.

Apollo’s revenue growth of 14% was slightly below the industry average of 15-16% for large hospital chains, but its ARPOB growth of 9.7% was among the highest, reflecting better case mix and pricing power.

Common Concerns and Misconceptions

A frequent misconception is that Apollo’s pharmacy segment drags down overall profitability. While it does have lower margins, the segment provides scale for procurement and patient data that feeds the hospital business. Another concern is debt: Apollo’s net debt stood at ₹3,200 crore as of December 2024, but the debt-to-EBITDA ratio improved to 1.1x from 1.4x, well within comfort levels.

Investors also often ask about the impact of insurance payouts. Around 40% of Apollo’s hospital revenue comes from cashless insurance, which carries a 15-30 day receivable cycle. The company has reduced average collection days to 42 from 48, easing working capital pressure.

How to Access and Interpret the Results

Apollo publishes its full results, press release, and investor presentation on its official website under the ‘Investors’ section, as well as on stock exchange filings at BSE and NSE. The earnings call transcript is typically available within 24-48 hours on the company site or third-party platforms like Trendlyne and Screener.in.

When reading the results, focus on three numbers beyond net profit: EBITDA margin (operational efficiency), ARPOB (pricing power and case mix), and occupancy rate (demand utilization). For pharmacy, watch same-store sales growth; for diagnostics, watch revenue per test.

Risks and Forward Outlook

Management guided for mid-teens revenue growth in FY26, with capex of ₹2,500 crore for new hospitals in Navi Mumbai and Indore. Key risks include rising employee costs due to nurse shortages, regulatory changes in pricing for medical devices, and potential slowdown in medical tourism if visa policies tighten.

The company also faces competition from new entrants like Aster DM and existing players like Narayana Health, which are expanding in Apollo’s strongholds of Chennai and Hyderabad. However, Apollo’s brand recognition and integrated model (hospitals + pharmacy + diagnostics) provide a moat that smaller chains lack.

Frequently Asked Questions

When will Apollo announce next quarterly results? The Q4 FY25 results are expected in mid-May 2025, typically within two weeks of the fiscal year end on March 31. The company usually announces the date a week in advance on stock exchanges.

Does Apollo pay dividends? Yes, Apollo has paid a dividend in most years. For FY24, it paid ₹15 per share. The final dividend for FY25 will be announced with the Q4 results, usually in May.

What is Apollo’s current market capitalization? As of early March 2025, Apollo’s market cap is approximately ₹1.2 lakh crore (₹120 billion), with shares trading around ₹8,500 on the NSE. This fluctuates daily with market conditions.

How does Apollo’s profit compare to its revenue? Net profit margin is around 7% of revenue, which is typical for Indian hospital chains. The lower margin reflects high fixed costs of equipment and staff, but the company’s EBITDA margin of 18% shows strong operational cash generation.

Are these results audited or provisional? Quarterly results are limited-reviewed by auditors, not fully audited. The full-year audited results are released at the end of the fiscal year. Investors should treat quarterly numbers as provisional until the annual audit.

What is the difference between standalone and consolidated results? Standalone results include only Apollo Hospitals Enterprise’s own operations, while consolidated includes subsidiaries like Apollo Health & Lifestyle (diagnostics), Apollo Pharmacies, and Apollo Munich Health Insurance (now HDFC ERGO). Most analysts focus on consolidated figures for a full picture.

Related

How pages are sourced and corrected: Sources and editorial policy.